Taft is pleased to have acted as legal counsel to ONL Therapeutics, Inc. in its oversubscribed $65 million Series D financing.

ONL Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease. Johnson & Johnson Innovation – JJDC, Inc. led the round that was backed by a consortium of investors that included Bios Partners, Novartis Venture Fund, and Visionary Ventures, amongst others. Read the release here.

Taft’s legal team was led by Sara Kruse and included Josh Borson, Bridget Tignanelli, Summer Moukalled, and Aaron Miller.